Over the past week, regulatory updates spanned approvals, safety statements and policy shifts. The FDA authorized imlunestrant for ESR1-mutated advanced breast cancer, while Australia’s TGA reversed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback